The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology

International Journal of Methods in Psychiatric Research

Volumn 19, Issue 4, 2010, Pages 195-210

  De Hert, Marc ^a   Mauri, Mauro ^b   Shaw, Ken ^c   Wetterling, Tilman ^d   Doble, Adam ^e   Giudicelli, Agnès ^f   Falissard, Bruno ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF PISA   (Italy)

^c PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^d Vivantes Klinikum Hellersdorf   (Germany)

^e Foxymed   (France)

^f SANOFI   (France)

^g Universite Paris Sud   (France)

Author keywords

Antipsychotics; Diabetes; Metabolic disorders; Prevalence; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; EASTERN EUROPE; EUROPE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; MALE; METABOLIC DISORDER; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EUROPE; EUROPE, EASTERN; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 78649544462     PISSN: 10498931     EISSN: 15570657     Source Type: Journal    
DOI: 10.1002/mpr.322     Document Type: Article

References (30)

1. American Psychiatric Association. (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, American Psychiatric Association.
2. Andrews E.A., Avorn J., Bortnichak E.A., Chen R., Dai W.S., Dieck G.S., Edlavitch S., Freiman J., Mitchell A.A., Nelson R.C., Neutel C.I., Stergachis A., Strom B.L., Walker A.M. (1996) Guidelines for Good Epidemiology Practices for drug, device, and vaccine research in the United States. Pharmacoepidemiology and Drug Safety, 5, 333-338.
3. Brown S., Inskip H., Barraclough B. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217.
4. Byrne M., Agerbo E., Mortensen P.B. (2002) Family history of psychiatric disorders and age at first contact in schizophrenia: an epidemiological study. British Journal of Psychiatry Supplement, 43, s19-s25.
5. Casadebaig F., Philippe A., Guillaud-Bataille J.M., Gausset M.F., Quemada N., Terra J.L. (1997) Schizophrenic patients: physical health and access to somatic care. European Psychiatry, 12, 289-293.
6. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., De Bacquer D., Ducimetiere P., Jousilahti P., Keil U., Njolstad I., Oganov R.G., Thomsen T., Tunstall-Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen L., Graham I.M. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal, 24, 987-1003.
7. Correll C.U. (2007) Balancing efficacy and safety in treatment with antipsychotics. CNS Spectrums, 12, 12-20, 35.
8. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health, 2, 14.
9. De Hert M., Schreurs V., Vancampfort D., van Winkel R. (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry, 8, 15-22.
10. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903-912.
11. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., Maj M., McIntyre R.S., Naber D., Newcomer J.W., Olfson M., Osby U., Sartorius N., Lieberman J.A. (2008) Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry, 69, 514-519.
12. Gasquet I., Gury C., Tcherny-Lessenot S., Quesnot A., Gaudebout P. (2005) Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients. Pharmacoepidemiology and Drug Safety, 14, 805-811.
13. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53.
14. Gottesman I.I. (1991) Schizophrenia Genesis. The Origins of Madness, W.H. Freeman.
15. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C. Jr, Spertus J.A., Costa F. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735-2752.
16. Hanssens L., De Hert M., Wampers M., Reginster J.Y., Peuskens J. (2006) Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clinical Practice and Epidemiology in Mental Health, 2, 11.
17. Henderson D.C. (2005) Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry Supplement, 66(6), 11-20.
18. IMS Health. (2006) [20 July 2010]
19. Lamberti J.S., Crilly J.F., Maharaj K., Olson D., Wiener K., Dvorin S., Costea G.O., Bushey M.P., Dietz M.B. (2004) Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. Journal of Clinical Psychiatry, 65, 702-706.
20. Mortensen P.B., Pedersen C.B., Westergaard T., Wohlfahrt J., Ewald H., Mors O., Andersen P.K., Melbye M. (1999) Effects of family history and place and season of birth on the risk of schizophrenia. New England Journal of Medicine, 340, 603-608.
21. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. (1996) Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68-73.
22. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., Lieberman J.A. (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86, 15-22.
23. Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs Supplement, 19(1), 1-93.
24. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research, 45, 21-28.
25. Ren X.S., Kazis L.E., Lee A.F., Hamed A., Huang Y.H., Cunningham F., Miller D.R. (2002) Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 27, 441-451.
26. Rosenbaum P., Rubin D. (1983) The central role of the propensity score in observational studies for causal effect. Biometrika, 70, 41-55.
27. Scheen A.J., De Hert M.A. (2007) Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes & Metabolism, 33, 169-175.
28. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 192, 406-411.
29. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R., Ebenbichler C.F. (2007) Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 61, 1356-1370.
30. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837-1847.